Has PolyNovo's (ASX: PNV) share price hit the bottom yet?
PolyNovo Limited (ASX: PNV) remains a fundamentally strong, high-growth medtech, but its share price is currently testing key support around A$0.88–0.92 within a broader sideways range. While selling pressure has eased and momentum is stabilising, a confirmed bottom would require a sustained break above A$1.08; otherwise, a fall below A$0.86–0.90 could signal further downside.
Is 4DMedical (ASX: 4DX) the Next High-Growth MedTech Breakout or a Funding Risk?
4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.
Why Cochlear's (ASX: COH) share price keeps crashing, and where can it find a bottom?
Cochlear’s share price slump reflects profit downgrades, slowing growth, weak global demand, and macro pressures. The stock is down sharply, but a lasting bottom likely depends on stabilising earnings and clearer signs of demand recovery.
Lumos Diagnostics (ASX: LDX) Shares Keep Sliding Despite Last Year’s Rally
Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.
PolyNovo (ASX: PNV): Our Bottoming Thesis Confirmed by a Breakout Move
PolyNovo (ASX: PNV) is an advanced wound care company whose NovoSorb platform drives strong U.S.-led growth. After the March weakness from leadership changes, improving revenues and a technical breakout above the trend signal a potential bottom and renewed bullish momentum.
Racura Oncology (ASX: RAC) - A High-Risk, High-Reward Oncology Play
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.